Search - tctmd.com

Displaying 1 - 20 of 33

Sort: Relevancy | Date

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

Presentation TCT 2023

Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-analysis of the TWILIGHT and TICO Randomized Trials

Presenter: Usman Baber

October 23, 2023

News Conference News SCAI 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

L.A. McKeown

May 22, 2023

News Daily News

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Yael L. Maxwell

November 21, 2022

News Daily News

Even With Revascularization in ISCHEMIA, Skipping Meds Hurt Health Status

Todd Neale

August 19, 2022

News Daily News

Heavy Calcification Levels PCI/CABG Playing Field at 10 Years: SYNTAXES

Yael L. Maxwell

January 06, 2022

News Daily News

De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis

Yael L. Maxwell

July 16, 2021

News Daily News

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

Michael O'Riordan

September 18, 2020

News Daily News

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Yael L. Maxwell

May 15, 2020

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

Presentation TCT 2019

TWILIGHT: A Deep Dive

Presenter: Usman Baber

September 26, 2019

Presentation TCT 2019

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Presenter: Usman Baber

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Presentation TCT 2019

Insights From TWILIGHT

Presenter: Usman Baber

September 26, 2019

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

Caitlin E. Cox

September 20, 2019

News Conference News SCAI 2019

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

Yael L. Maxwell

May 24, 2019

News Conference News ACC 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

Caitlin E. Cox

March 17, 2019

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

Presentation TCT 2018

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Usman Baber

September 23, 2018

Advertisement

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-analysis of the TWILIGHT and TICO Randomized Trials

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Even With Revascularization in ISCHEMIA, Skipping Meds Hurt Health Status

Heavy Calcification Levels PCI/CABG Playing Field at 10 Years: SYNTAXES

De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

TWILIGHT: A Deep Dive

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Insights From TWILIGHT

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content